Evgen Pharma Share Discussion Threads

[moneymunch] 10/10/2020 08:58

Lol...i don't, but unlike you i hope both prove to be effective treatments. Gl ;-)

[nobbygnome] 10/10/2020 08:55

If you think SFX01 is in some way a threat for SNG you are deluded!

What I really don't like is posters deliberately misleading other investors by posting lies.

[moneymunch] 10/10/2020 08:44

Lol...how many more......nothing was made up, mere speculation on the information at hand....SFX-01's patient trials were expected to be underway in July, and the following weeks saw a dramatic reduction in Scottish deaths, you didn't like it because your thought it might effect your investment at SNG, during which time you spent plenty of time ramping SNG on the EVG thread and bashing EVG both here and no doubt on your secret squirrel thread..... Gla Holders.....fingers crossed that we get news this week on the status of the Covid-19 patient trials and good luck to all reasonable investors at SNG, especially those who bought at the top. ;-)

[peanut100] 10/10/2020 08:06

Agree but did it not start 1/10?

[moneymunch] 09/10/2020 22:48

You too lovewin, I'm not going anywhere soon even if this hits £1 and more, obviously I'll take so.e profit, but the more I look at the panacea potential of sulforaphane and SFX-01's potency towards Nrf2 and STAT3 pathways , the more I'm convinced that this could be huge....Jim Mellon has just invested £250k because of its anti-aging properties...google STAT3 and see how many BIO's are targeting it at the moment, cash well as NRF2...the potential Transformational upside is tremendous, but obviously we need some good news towards its progress....if SFX-01 was proven to be a therapeutic benefit for the treatment of ARDS/Covid-19, then £5 plus for starters...the same value for SFX-01 as the standard treatment for breast cancer, when all other drugs have failed...Gl :-)

Ps I haven't eaten so much Broccoli since I've been invested....at least 3 times a week from the one who cooks my meals...:-)))

[lovewinshatelosses] 09/10/2020 22:30

Fair enough MM. I remain a firm holder here, with a top slice target far north of this and willing the new boss to take this company into a new league.
Anyway, have a nice weekend.

[moneymunch] 09/10/2020 22:27

Ps got tickets to see this band in April, Pryzm in Kingston, Covid-19 permitting...:-)))

[moneymunch] 09/10/2020 22:18

Certainly not lovewin, but there were a few others, and I take no pleasure in punters losing money, I want every genuine pi to do well ( but it's not that easy as we all know ) but i take umbrage if punters try and undermine a stock where I'm invested and promote another stock at EVG's expense ....you get what you give imho...and the ( few ) that appears invested in EVG are going to get much more than they're expecting ...GL...On and seriously UP!!!..;-)

[lovewinshatelosses] 09/10/2020 22:00

I trust you are not referring to me MM? If so, I locked in some nice profits and am on a free carry with both SNG and 4D. I am however sitting patiently on a paper loss here, but ready for this exciting UPside that we all wait with baited breath for :)

[bocker01] 09/10/2020 21:43

It started a week ago Enter and patients are now being enrolled. I suspect the run rate will gather momentum fast. It will take a while to get the full 300. But then it will be pretty conclusive and relate to ARDS generally where a huge treatment gap exists. As Covid has shown. 2m a year suffer from ARDS many ending up in ICU and many sadly dying. Personally though I’m thinking we may get a breast cancer update in five or six weeks. Wouldn’t to be out when that happens.

[moneymunch] 09/10/2020 21:39

Ha ha ha ha ha...Gla laughers...:-)

Ps could be worse , if you sold EVG and bought SNG and DDDD on the spike, especially if you made a point of highlighting it on the EVG thread :-(

[enter] 09/10/2020 17:39

Glad you can laugh about it. We need some news here. Can't believe there hasn't been any announcement about the trial of SFX-01 in Covid patients yet.

[lovewinshatelosses] 09/10/2020 16:42

Quite so Bumpa! Be still my beating heart...

[bumpa33] 09/10/2020 16:41

Gotta say, if this level of excitement keeps up I’m gonna have a coronary 🙄

[lovewinshatelosses] 09/10/2020 12:00

Certainly hope so MM.

[moneymunch] 09/10/2020 06:52

James D Chalmers Retweeted
Peter Horby
@PeterHorby
·
8h
RECOVERY publication on hydroxychloroquine finally out. Hydroxychloroquine is not effective in hospitalised COVID patients. Disappointing, but allows us to focus our efforts on promising new treatments.

hTps://nejm.org/doi/full/10.1056/NEJMoa2021436?query=featured_coronavirus

[moneymunch] 08/10/2020 22:19

Ps lovewinhatelosers, one would assume that SFX-01's phase 2b patient trials for breast cancer are in the planning. Gl :-)





Potential transformational news stacking up.....SFX-01's phase 2 breast cancer results were outstanding .......news of their phase 2b trials coming soon and every chance of a commercial JV in the pipeline given that the results were "life changing for some patients"....exciting times...;-)





Rob Clarke Retweeted
Ed Tate
@TateScience
·
Jul 3

Read new #breastcancer research from @MCRBreastCentre with contributions from @tatescience & others, on targeting STAT3 signalling in ER+ breast cancers in @oncogenejournal



Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

......................

Rob Clarke
@RobClarkeLab
·
Jun 24
We’re looking for a talented student to carry out a PhD starting this September: Understanding the role of STAT3 in therapy-resistance and metastatic progression of breast cancer (MRC CASE) at The University of Manchester on hxxp://FindAPhD.com


About the Project

Resistance to endocrine and other therapies during metastatic progression is the major cause of mortality in breast cancer. We have previously reported that endocrine resistance can be driven by ALDH+ breast cancer stem cells (CSCs) and more recently that STAT3 is activated in these cells (Simoes et al., 2015 and 2020). We and others have reported that breast cancers resistant to the recently FDA-approved CDK4/6 inhibitors such as Palbociclib have increased numbers of CSCs and activation of STAT3 signalling, and that inflammatory and obesity-related breast cancer are driven by IL6 and leptin activating STAT3 transcriptional activity.

Our hypothesis is that targeting STAT3 would benefit breast cancer patients where CSCs are driven by the STAT3 signalling pathway, and in particular would combat therapy resistance and metastatic progression. In the Clarke lab, we have established in vitro and in vivo models of breast cancer patient-derived organoids and xenografts that metastasise to relevant organs such as lung and bone (Byrne et al., 2017, Eyre et al., 2019). The student will use these models to perform CSC assays, gene and protein expression analyses to characterise the signalling pathways targeted by SFX-01 and discover biomarkers that predict response.

The potential outcome is the definition of which breast cancers have STAT3 dependency and are sensitive to STAT3-targeted therapies. We aim to understand the mechanisms of STAT3 signalling and establish predictive biomarkers that will have translational value in precision medicine clinical trials, which the appointed student would help design during a placement in the iCASE partner company Evgen Pharma PLC, who aim to develop SFX-01 for improved breast cancer therapy.

[moneymunch] 08/10/2020 19:34

No such problem for Evgen...SFX-01 is in evaluation for multiple disease targets and funded by leading academic research organisations, independent from each other, and so resources aren't focused solely on Covid-19 like so many others. Gl :-)

[lovewinshatelosses] 08/10/2020 18:09

On positive covid news, I would expect considerably more than 50-100% movement in a single trading day, unless the RNS fell late PM, or if one of the other outfits had a universally accepted vaccine or other highly valued product nailed first, especially one of the big boys.
I would really like to know where we are regarding the breast cancer trials though.
In some ways, I am concerned that a lot of companies that are chasing the Covid silver bullet are putting their real potential show-stoppers at the back of the line.
That is the job of the various management teams to avoid losing sight of, but our job as shareholders to keep them to account on. That said, I will settle for a Covid silver bullet while we wait :)

[stockhunters] 08/10/2020 16:28

not long now

[moneymunch] 08/10/2020 15:31

and it keeps on rising :-(

Scottish numbers:

8 October 2020

Summary

1,027 new cases of COVID-19 reported; this is 13.5% of newly tested individuals

5 new reported death(s) of people who have tested positive

31 people were in intensive care yesterday with recently confirmed COVID-19

377 people were in hospital yesterday with recently confirmed COVID-19

18,796 new ;tests for COVID-19 that reported result

............

Scottish numbers:

30 September 2020

640 new cases of COVID-19 reported; this is 10.3% of newly tested individuals.

7 new reported death(s) of people who have tested positive

15 people were in intensive care yesterday with recently confirmed COVID-19.

137 people were in hospital yesterday with recently confirmed COVID-19.

15,629 new tests for COVID-19 that reported results.

[moneymunch] 07/10/2020 20:56

One thing for sure, is that if SFX-01's phase 2/3 Covid-19 patient trials were successful and SFX-01 was confirmed a therapeutic benefit for the effects of ARDS/ Covid-19, then Evgen's market cap would be valued in $100's of millions as opposed to its current £17m....undoubted Transformational potential on several fronts...Excitement cranking UP as we await an imminent UPdate on proceedings. Gla :-)

Ps Every chance!!! :-)

“It is crucial to understand the most appropriate context for introducing an anti-inflammatory therapy to complement an antiviral therapy. Such therapy must control inflammation without altering the ability of the host to mount an efficient adaptive immune response against the virus.

We propose that boosting endogenous cellular defenses by targeting the cytoprotective transcription factor Nrf2 (gene name NFE2L2) will promote the resolution of COVID-19 associated inflammation and also restore redox homeostasis and facilitate tissue repair.

The isothiocyanate sulforaphane (SFN) is the most potent naturally occurring NRF2 activator, with well-documented antioxidant and anti-inflammatory effects. The high bioavailability of SFN makes it an excellent candidate for alleviating excessive anti-inflammatory responses and protecting the lungs.

Even though Nrf2 is the primary mediator, additional factors contribute to the anti-inflammatory effects of SFN. SFN inhibits NF-κB, inhibitor of NF-κB kinase subunit β (IKKβ), and STAT3.

By regulating the endogenous cytoprotective systems, Nrf2 may have a more physiological role in achieving a balance between the beneficial and adverse effects of inflammation. Nrf2 inhibits IL-6 and IL-1β gene expression.

Antioxidant and cytoprotective effects of Nrf2 activation are long-lasting and persist for several days after inducer elimination. They are mediated by enzymes that, in contrast to small molecules, have long half-lives and are not consumed, and are instead regenerated during the reactions which they catalyze.”

Activation of Nfr2 Be a Strategy against COVID-19?”

[moneymunch] 07/10/2020 18:51

With the surge of new cases, news of SFX-01's Covid-19 Patient trials must be imminent imho....and the following adds weight to SFX-01's prospects in treating ARDS/Covid-19 being a potent activator of Nrf2. Gla ;-)



Multiple sclerosis drug dimethyl fumarate may suppress viral multiplication and reduce inflammation in COVID-19 patients

October 05, 2020 22:00:31 IST

A number of drugs like remdesivir specifically target the RNA polymerase of SARS-CoV-2, causing it to stop multiplying while other drugs like hydroxychloroquine focus on reducing inflammation, a possible cause of death in coronavirus patients.

COVID-19 is a viral disease caused by the SARS-CoV-2 virus. Since the disease is still new and viruses are intracellular parasites (they need a living host to survive), scientists are studying how the virus works, as extensively as possible, so an effective antiviral therapy or drug can be developed against it.

A number of drugs like remdesivir specifically target the RNA polymerase of SARS-CoV-2, causing it to stop multiplying while other drugs like hydroxychloroquine focus on reducing inflammation, a possible cause of death in coronavirus patients.

Now, a group of researchers at the Aarhus University, Denmark claim that a multiple sclerosis drug called dimethyl fumarate (DMF) can suppress the growth of a wide range of viruses including the COVID-19 causing virus SARS-CoV-2 and may hence be effective in the treatment of the disease.

The findings of the research study are published in the peer-reviewed journal Nature Communications.

Multiple sclerosis is a chronic condition of the central nervous system in which a person’s own immune system attacks and damages the brain cells, causing symptoms like fatigue, pain, muscle stiffness and spasms, numbness, tingling, depression and anxiety.

NRF2, 4-octyl-itaconate and DMF

NRF2 is a protein that is involved in the process of transcription (conversion of DNA to RNA) in body cells. During homeostasis (normal conditions) another compound called KEAP1 ensures that NRF2 is present in its inactive state inside the cell. However, when oxidative stress increases, KEAP1 gets inactivated and NRF2 activates. The latter then leads to the transcription of certain genes that can prevent tissue damage caused due to infection. NRF2 also regulates inflammation by suppressing the production of certain inflammatory compounds like interleukin (IL-) 1beta.

Oxidative stress is a term used to denote the imbalance between free radicals and antioxidant compounds in our body. The condition generally leads to tissue damage.

Previous studies have shown that small molecules, including itaconate and fumarate, can induce NRF2 to help manage inflammation. 4-octyl-itaconate, specifically, was shown to be an effective inducer of NRF2. DMF has been approved by the US Food and Drug Administration for the treatment of multiple sclerosis as the condition is marked by inflammation.

[moneymunch] 07/10/2020 14:30

Very nice, and hopefully an indication that there are very little shares left in free float.....another 40k just gone through and so a few more of those and we'll be back to 14p plus in a blink....Fingers crossed for a surge into close in anticpation of imminent news from the new CEO....Gl ;-)